<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02589392</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.29110</org_study_id>
    <nct_id>NCT02589392</nct_id>
  </id_info>
  <brief_title>Cetaphil Restoraderm Effect on Young Children With Atopic Dermatitis</brief_title>
  <official_title>Effect of Cetaphil® Restoraderm® Moisturizer on Very Dry Skin in Children With a Controlled Atopic Dermatitis:a Randomised, Parallel Group Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of Cetaphil® Restoraderm® skin restoring
      moisturizer in reducing the signs and symptoms of very dry atopic skin in young children.
      Subjects with atopic dermatitis (AD) in remission phase will be randomized to receive either
      Cetaphil® Restoraderm® skin restoring body wash only, or the same body wash in association
      with Cetaphil® Restoraderm® skin restoring moisturizer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>The duration between Baseline and the first AD relapse occurs (from randomization to last visit at 12 weeks)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Moisturizer + Body wash</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cetaphil® Restoraderm® moisturizer (2/day) + Cetaphil® Restoraderm® Skin body wash (1/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Body wash</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cetaphil® Restoraderm® body wash (1/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cetaphil® Restoraderm® moisturizer + Cetaphil® Restoraderm® body wash</intervention_name>
    <arm_group_label>Moisturizer + Body wash</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cetaphil® Restoraderm® body wash</intervention_name>
    <arm_group_label>Body wash</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject, aged 2 to 12 years inclusive

          -  Controlled mild to moderate atopic dermatitis with a Investigator Global Assessment
             score at 0 or 1, within one week after successful treatment with topical
             corticosteroid.

        Exclusion Criteria:

          -  Subject presenting bacterial, viral, fungal or parasite skin infection

          -  Subject with ulcerated lesions, acne or rosacea

          -  Immunosuppression

          -  Subject with a wash-out period from baseline for topical treatment less than 8 days
             for Calcineurin inhibitor

          -  Subject with a wash-out period from baseline for topical treatment more than 8 days
             for corticosteroid

          -  Subject with a wash-out period from baseline for systemic treatment less than 8 days
             for anti-histamines, less than 4 weeks for immunomodulators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Children's Hospital</name>
      <address>
        <city>Xi Cheng District</city>
        <state>Beijing</state>
        <zip>100045</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's hospital</name>
      <address>
        <city>Shenzhen city</city>
        <state>Guangdong</state>
        <zip>518026</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunan Children's Hospital</name>
      <address>
        <city>Hunan</city>
        <state>Hunan</state>
        <zip>410007</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XinHua Hospital</name>
      <address>
        <city>Yangpu</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asian Hospital and Medical Center</name>
      <address>
        <city>Manila</city>
        <state>Muntinlupa City</state>
        <zip>1780</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jose R. Reyes Memorial Medical Center</name>
      <address>
        <city>Manila</city>
        <zip>1003</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philippine General Hospital</name>
      <address>
        <city>Metro Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Taguig City</city>
        <zip>1634</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Philippines</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2015</study_first_submitted>
  <study_first_submitted_qc>October 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2015</study_first_posted>
  <last_update_submitted>March 1, 2016</last_update_submitted>
  <last_update_submitted_qc>March 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>February 15, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

